A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T-Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s).

Trial Profile

A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T-Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s).

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2014

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Lung transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Neovii Biotech
  • Most Recent Events

    • 10 Apr 2014 Results presented at the 34th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 07 Jun 2012 Actual patient number changed from 222 to 223 as reported by ClinicalTrials.gov.
    • 15 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top